Genetic Technologies Return on Investment 2010-2022 | GENE
Current and historical return on investment (ROI) values for Genetic Technologies (GENE) over the last 10 years.
| Genetic Technologies ROI - Return on Investment Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | LT Investments & Debt | Return on Investment |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Biomedical and Genetics | $0.028B | $0.005B |
| Genetic Technologies was the first company in the world to recognize important new applications for `non-coding` DNA (DeoxyriboNucleic Acid). The Company has since been granted patents securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all multicellular species. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bristol Myers Squibb (BMY) | United States | $158.293B | 9.67 |
| GSK (GSK) | United Kingdom | $71.300B | 9.41 |
| Bio-Rad Laboratories (BIO.B) | United States | $12.069B | 28.64 |
| QIAGEN (QGEN) | Netherlands | $11.249B | 19.20 |
| Ginkgo Bioworks Holdings (DNA) | United States | $3.996B | 0.00 |
| Myovant Sciences (MYOV) | United Kingdom | $2.614B | 0.00 |
| Arcus Biosciences (RCUS) | United States | $1.485B | 22.29 |
| Biohaven (BHVN) | United States | $1.240B | 0.00 |
| Emergent Biosolutions (EBS) | United States | $0.697B | 5.48 |
| ADC Therapeutics SA (ADCT) | Switzerland | $0.356B | 0.00 |
| Enzo Biochem (ENZ) | United States | $0.070B | 0.00 |
| Ambrx Biopharma (AMAM) | United States | $0.070B | 0.00 |
| SQZ Biotechnologies (SQZ) | United States | $0.024B | 0.00 |
| Gelesis Holdings (GLS) | United States | $0.024B | 0.00 |
